|
Vaccine shows promise for melanoma
|
|
“The experimental vaccine offers hope to a patient population in need of more effective therapies with far fewer and more tolerable adverse events, particularly when compared with currently available therapies,” says Craig L. Slinglu Jr., M.D. |
|
ADVERTISEMENT
|
|
|
|
|
Cutaneous melanoma standard of care
|
|
“The standard of care for primary cutaneous melanoma may slowly be changing in light of the recent advancements and positive outcomes we are seeing with Mohs surgery, slow Mohs and new genetic molecular tests for diagnosis and prognosis of the tumor,” says M. Laurin Council, M.D., FAAD, FACMS |
|
|
|
|
No-cost BRAF test aids therapeutic decision making
|
|
“Dermatologists need to be actively and intellectually-engaged in the multi-disciplinary team. We aren’t responsible for administering systemic melanoma therapies, but knowing the BRAF status of a patient’s tumor allows us to understand which treatment options are available for these patients. It also helps dermatologists to be better prepared for drug reactions or side effects,” Sancy Leachman, M.D., says. |
|
|
|
Melanoma management perspectives vary
|
|
“Unfortunately, there is no real consensus on several different aspects of the management of the primary melanoma lesion. Many of the recommendations from the National Comprehensive Cancer Network (NCCN) are vague, leaving much up to the interpretation of the clinician and reliance on their training,” says Emmanuel M. Gabriel, M.D., Ph.D. |
|
Connect with us on Twitter and Facebook for daily updates.
|
|
|
|
|
|
|
|
|
|
